Pavan joined Kronos Bio in 2020 with a background in oncology and experience in clinical biomarkers, translational development, and companion diagnostics (CDx). Prior to Kronos Bio, Pavan led the Translational Sciences function at 28-7 Therapeutics focusing on RNA binding proteins and their role in Cancer. Before that, he built and led the Biomarkers and CDx department at H3 Biomedicine, focusing on developing and executing a biomarker strategy for targeted therapies across multiple hematological and solid tumor indications. Other experiences include clinical assay development and biomarker discovery at Eisai Pharmaceuticals and Somagenics. Pavan received a Ph.D. from University of California, Davis with a designated emphasis in Biotechnology.